Recent advances in treatment of patients with castration-resistant prostate cancer after docetaxel failure / 浙江大学学报·医学版
Journal of Zhejiang University. Medical sciences
;
(6): 115-118, 2014.
Article
Dans Chinois
| WPRIM
| ID: wpr-251713
ABSTRACT
The standard first-line treatment of castration-resistant prostate cancer (CRPC) is docetaxel-based chemotherapy. However, CRPC may not respond to docetaxel due to drug resistance or other causes. Several new therapeutic agents have been developed, some of which are approved by FDA or on clinical trials. The mechanisms of action of these agents include stabilizing microtubules, inhibiting hormone synthesis, blocking androgen receptor, bone targeting or immune regulation. In this article we review the novel therapeutic options for CPRC after docetaxel failure.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Anatomopathologie
/
Tumeurs osseuses
/
Résistance aux médicaments antinéoplasiques
/
Taxoïdes
/
Utilisations thérapeutiques
/
Traitement médicamenteux
/
Tumeurs prostatiques résistantes à la castration
Limites du sujet:
Humains
/
Mâle
langue:
Chinois
Texte intégral:
Journal of Zhejiang University. Medical sciences
Année:
2014
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS